Highlights Demant A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:37 2024-05-15 am EDT			5-day change	1st Jan Change
325.8 ^DKK	+0.80%		+1.69%	+10.07%

May. 06	DEMANT : Q1 sales miss; organic growth guidance unchanged
May. 06	Transcript : Demant A/S, Q1 2024 Interim Management Statement Call, May 06, 2024

DEMANT : Q1 sales miss; organic growth guidance unchanged	May. 06
Hearing Healthcare Company Demant Affirms FY24 Outlook	May. 06	MT
Demant A/S Provides Earnings Guidance for the Year 2024	May. 06	CI
Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business	Apr. 03	MT
Demant Seeks Acquisitions	Mar. 12	CI
DEMANT : In-line Q4; markets cheer the promising takeaways for 2024	Feb. 06
Global markets live: BP, Palantir, Infineon, Toyota, UBS...	Feb. 06
Tranche Update on Demant A/S's Equity Buyback Plan announced on March 5, 2021.	Feb. 06	CI
Demant A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06	CI
Demant Forecasts Up to 8% Organic Revenue Growth in FY24	Feb. 06	MT
Demant A/S Provides Earnings Guidance for the Year 2024	Feb. 05	CI
Demant to Recommence Share Buybacks	Nov. 21	MT
Demant Q3 revenue meets forecast, narrows outlook	Nov. 07	RE
Demant A/S Provides Earnings Guidance for the Year 2023	Nov. 07	CI
European Commission OKs Cochlear's Aquisition of Oticon Medical Unit	23-10-10	MT
Tranche Update on Demant A/S's Equity Buyback Plan announced on March 5, 2021.	23-08-15	CI
Demant A/S Updates Earnings Guidance for 2023	23-08-15	CI
Demant A/S Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-15	CI
UK Competition Watchdog Accepts Undertakings in Demant's Hearing Implants Division Sale to Cochlear	23-08-02	MT
Demant Flags Greater 2023 Loss from Hearing Implants Unit Sale After UK Regulator Modifies Deal	23-06-22	MT

No results for this search

DEMANT : Q1 sales miss; organic growth guidance unchanged

May 06, 2024 at 11:18 am EDT